There are various reports on the efficacy of PCSK9 inhibitors in LDL-C lowering in a variety of comprehensive large-scale clinical trials such as PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in Different Populations) [17,18,19,20,21,22], FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk) [23,24,25] and ODYSSEY (Cardiovascular Outcomes After an Acute Coronary Syndrome) [26,27,28]. Here, PCSK9 is linked to acute coronary syndrome.